Canaccord lowered the firm’s price target on Voyager Therapeutics (VYGR) to $12 from $14 and keeps a Buy rating on the shares. The firm said ...

Canaccord raised the firm’s price target on Phreesia (PHR) to $35 from $34 and keeps a Buy rating on the shares. The firm said they remain ...

TransMedics Group (NASDAQ:TMDX – Get Free Report)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a ...

Stride (NYSE:LRN – Get Free Report) had its price objective increased by Canaccord Genuity Group from $135.00 to $145.00 in a research report issued on Tuesday,Benzinga reports. The brokerage ...

Analysts at Canaccord Genuity slashed their target price on mining services firm Capital from 130.0p to 60.0p on Tuesday and ...

Canaccord Wealth has taken a significant step in its global expansion by opening a permanent office in Dubai’s financial hub, ...

CG Partners Limited Partnership, a 10% Holder, acquired 18,000 Common Shares on an indirect ownership basis for registered holder Canaccord Genuity Corp. at a price of $8.420 on March 12th, 2025. This ...

On Wednesday, Canaccord Genuity revised its price target for Cybin Inc. (NYSE:CYBN) shares, reducing it to $73.00 from the previous $86.00, while continuing to endorse the stock with a Buy rating.

Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to ...

Tesla stock has distractions from protests, sales declines and Elon Musk's role with the DOGE. An analyst isn't ready to throw in the towel yet.

Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc ...